

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of China Pioneer Pharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Hui Lap Keung (許立強) (“**Mr. Hui**”) has been appointed as a non-executive director of the Company with effect from 19 June 2019.

The biography of Mr. Hui is set out below:

Mr. Hui, also known as Patrick Hui, aged 50, has extensive experience in investment management and securities brokerage. Prior to joining the Group and since July 2018, Mr. Hui has served as a responsible officer and fund manager of Golden Great China Fund Management Limited, a corporation licensed to carry out Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). From November 2008 to May 2018, Mr. Hui worked at Prudential Brokerage Limited, PCA Wealth Management Limited, Prudential Capital Asia Limited and Prudential Index Trading Company Limited, the above companies principally engaged in corporate finance, securities brokerage and wealth management for the Greater China Region, with his last position as Investment Director – China. Prior to that, Mr. Hui had worked at several wealth management, financial and banking institutions. From November 2016 to March 2017, Mr. Hui was an executive director of Kiu Hung International Holdings Limited (stock code: 00381), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. Hui obtained a Diploma of Business Studies from Hang Seng School of Commerce in 1991 and a Diploma of Management Studies from the Hong Kong Management Association in 1998. He obtained a Bachelor of Applied Finance from the University of South Australia in 2005.

Mr. Hui has entered into an appointment letter with the Company for a term of three years commencing from 19 June 2019 and his appointment is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the articles of association of the Company. Mr. Hui is entitled to an annual salary of HK\$240,000 pursuant to the appointment letter, which is determined with reference to his duties and responsibilities in the Group and the market rate for the position.

Save as disclosed above, as at the date of this announcement, Mr. Hui (i) does not hold any other position in the Company or any of its subsidiaries; (ii) has no relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as such terms are defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; and (iii) has not held any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years.

As at the date of this announcement, Mr. Hui was not interested (within the meaning of Part XV of the SFO) in the shares or any other securities of the Company.

Save as disclosed above, Mr. Hui confirmed that there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and the Company is not aware of any other matter in relation to Mr. Hui’s appointment as set out above that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to express its warmest welcome to Mr. Hui in joining the Board.

By Order of the Board
China Pioneer Pharma Holdings Limited
LI Xinzhou
Chairman

Hong Kong, 19 June 2019

As at the date of this announcement, the Directors of the Company are Mr. LI Xinzhou and Mr. LUO Chunyi as executive Directors, Mr. WANG Yinping, Mr. WU Mijia and Mr. HUI Lap Keung as non-executive Directors and Mr. ZHANG Hong, Mr. YAN Guoxiang and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.